Beijing T-MAX Biotech

Tianguangshi (Beijing T-MAX Biotech) is a clinical-stage biopharmaceutical company specializing in the discovery and development of therapeutic antibodies for oncology and autoimmune diseases. The company leverages its proprietary Mab-Glyco platform to engineer antibodies with enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) activity, aiming to improve clinical efficacy over existing treatments. Its lead candidate, MIL62, is a next-generation glycoengineered anti-CD20 antibody currently in Phase 3 trials for various B-cell malignancies. Additionally, the company has successfully commercialized MIL60, a bevacizumab biosimilar, in partnership with Betta Pharmaceuticals. Tianguangshi maintains a robust pipeline of bispecific antibodies and ADCs targeting high-value pathways such as Claudin 18.2 and HER2.